EUVIMEDEUVIMED entdecken
Open Access

Cost-Effectiveness of Continuous Glucose Monitoring With Remote Patient Monitoring in Pediatric Patients With Newly Diagnosed Type 1 Diabetes in the U.S.

Paul Dupenloup iD, Yupeng Chen, Priya Prahalad, Ramesh Johari, Ananta Addala, Dessi P Zaharieva, Ming Yeh Lee, David M Maahs, David Scheinker, Margaret L Brandeau, 4T Research Team*

Diabetes Care · 01.05.2026 · 49 (5) · 889-897

DOI: 10.2337/dc25-2825 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 25.03.2026. Verfasst von Paul Dupenloup und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Management Science and Engineering, Stanford University, Stanford, CA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Blood Glucose Self-Monitoring. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Stanford School of Medicine Research Office, Stanford HAI, The Helmsley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE The use of continuous glucose monitoring (CGM) with remote patient monitoring (RPM) continues to grow. We evaluated the cost-effectiveness of CGM with RPM compared with self-monitoring of blood glucose (SMBG) and CGM alone. RESEARCH DESIGN AND METHODS We simulated type 1 diabetes progression with a Markov model in 5-year-old patients over a 20-year, 50-year, and lifetime horizon. We tracked diabetic ketoacidosis (DKA), severe hypoglycemia (SH), and seven chronic complications: retinopathy, neuropathy, nephropathy, cardiovascular disease, end-stage renal disease, lower-extremity amputation, and blindness. We compared three interventions: SMBG, CGM, and CGM with RPM. Efficacy estimates were derived from meta-analyses of pediatric CGM studies and the results of the Teamwork, Targets, Technology, and Tight Glycemia Study (4T Study 1). We evaluated quality-adjusted life years (QALYs) and health care costs (2022 U.S. dollars) discounted at 3% annually. We performed extensive sensitivity analyses. RESULTS Compared with SMBG, CGM increased QALYs by 0.09 and costs by $8,900 over 20 years; CGM with RPM increased QALYs by 0.37, and costs by $10,300. CGM with RPM yielded more QALYs at a lower incremental cost-effectiveness ratio compared with CGM ($27,400/QALY vs. $103,700/QALY, respectively). Results were robust across sensitivity analyses and time horizons. CGM with RPM remained cost-effective when achieving at least 30% of 4T’s clinical efficacy. CONCLUSIONS CGM with RPM delivers superior health outcomes compared with SMBG and CGM and is likely cost-effective for patients with newly diagnosed type 1 diabetes. Despite higher intervention costs, CGM with RPM can reduce complications costs and generate net health care savings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Blood Glucose Self-MonitoringHumansContinuous Glucose MonitoringCost-Benefit AnalysisChildCost-Effectiveness AnalysisRemote Patient MonitoringQuality-Adjusted Life YearsFemaleMarkov ChainsBlood GlucoseChild, PreschoolUnited StatesMale

Substanzen

Blood Glucose

Autor:innen und Institutionen

  • Department of Management Science and Engineering, Stanford University, Stanford, CA.
  • Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University, Stanford, CA.
  • Stanford Diabetes Research Center, Stanford University, Stanford, CA.
  • Clinical Excellence Research Center, Stanford University, Stanford, CA.
  • Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, CA.

ORCID-Profile: Paul Dupenloup

Förderung

  • Stanford School of Medicine Research Office
  • Stanford HAI
  • The Helmsley Charitable Trust
  • NIDDK NIH HHS
  • Stanford Maternal & Child Health Research Institute
  • NCRR NIH HHS
  • Lucile Packard Children's Hospital Auxiliaries Endowment
  • NCATS NIH HHS

Zitieren

APA

Dupenloup, P., Chen, Y., Prahalad, P., Johari, R., Addala, A., Zaharieva, D. P., Lee, M. Y., Maahs, D. M., Scheinker, D., Brandeau, M. L., & 4T Research Team* (2026). Cost-Effectiveness of Continuous Glucose Monitoring With Remote Patient Monitoring in Pediatric Patients With Newly Diagnosed Type 1 Diabetes in the U.S. Diabetes Care, 49(5), 889-897. https://doi.org/10.2337/dc25-2825

Vancouver

Dupenloup P, Chen Y, Prahalad P, Johari R, Addala A, Zaharieva DP, et al. Cost-Effectiveness of Continuous Glucose Monitoring With Remote Patient Monitoring in Pediatric Patients With Newly Diagnosed Type 1 Diabetes in the U.S. Diabetes Care. 2026;49(5):889-897. doi:10.2337/dc25-2825

BibTeX
@article{Dupenloup2026,
  author = {Dupenloup, Paul and Chen, Yupeng and Prahalad, Priya and Johari, Ramesh and Addala, Ananta and Zaharieva, Dessi P and Lee, Ming Yeh and Maahs, David M and Scheinker, David and Brandeau, Margaret L and 4T Research Team*, 4T Research Team*},
  title = {Cost-Effectiveness of Continuous Glucose Monitoring With Remote Patient Monitoring in Pediatric Patients With Newly Diagnosed Type 1 Diabetes in the U.S},
  journal = {Diabetes Care},
  year = {2026},
  volume = {49},
  number = {5},
  pages = {889--897},
  doi = {10.2337/dc25-2825}
}
Kostenlos starten →